Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0XL4I
|
|||
| Former ID |
DPR000135
|
|||
| Drug Name |
ER-319711-15
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Preclinical | [1] | |
| Company |
Eisai Co Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dipeptidyl peptidase 4 (DPP-4) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Protein digestion and absorption | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl pepti... J Pharmacol Exp Ther. 2006 Dec;319(3):1253-7. | |||
| REF 2 | Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.